Mark Stetter
Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting.
Highest-materiality recent filing
Zoetis Q1 revenue flat organic; cuts FY 2026 guidance on softer demand and competition
Revenue $2.3B, +3% reported but flat organic; net income $601M ($1.42 EPS), flat YoY.
Zoetis Q4 2025 revenue $2.4B (+3%), EPS $1.37; FY26 guidance $9.825-10.025B
Q4 2025 revenue $2.4B (+3% reported, +4% organic); net income $603M (EPS $1.37, +6%).
Zoetis issues $2B of 0.25% convertible notes due 2029; proceeds for stock buyback and capped calls
Aggregate principal $2.0B (including $250M option exercised); 0.25% semi-annual interest; matures June 15, 2029.
Zoetis Q3 adjusted EPS $1.70 (+8%); revenue $2.4B (+4% organic); FY guidance narrowed
Q3 revenue $2.4B (+1% reported; +4% organic operational); net income $721M, $1.63 diluted EPS (+9% YoY).
Zoetis Q2 revenue $2.5B (+4% reported, +8% organic); raises FY2025 guidance
Reported net income $718M ($1.61 diluted EPS), up 15% YoY; adjusted EPS $1.76, up 13%.
Effective May 21, 2025, Dr. Mark Stetter was elected to the Board of Directors of the company at the Annual Meeting.
Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc.
Max materiality 0.75 · Median 0.45 · Most common event dividend